Literature DB >> 16963027

Moderate overexpression of AIB1 triggers pre-neoplastic changes in mammary epithelium.

Alvaro Avivar1, María Carmen García-Macias, Emma Ascaso, Guadalupe Herrera, José-Enrique O'Connor, Jaime Font de Mora.   

Abstract

Here we report a new model of pre-clinical breast cancer which has been generated by overexpressing the steroid receptor coactivator AIB1 at moderate levels in breast epithelium. Transgenic female mice display mammary hyperplasia at the onset of puberty, consistent with enhanced proliferation of primary mammary epithelial cultures and augmented levels of cyclin D1 and E-cadherin. Studies of BrdU incorporation revealed that AIB1 localizes to the nucleus during or after S phase, implicating a new role for AIB1 in cell-cycle progression subsequent to G1. Our findings suggest that moderate overexpression of AIB1 may represent one of the pre-neoplastic changes in breast tissue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16963027     DOI: 10.1016/j.febslet.2006.08.057

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.

Authors:  Rebecca E Nakles; Maddalena Tilli Shiffert; Edgar S Díaz-Cruz; M Carla Cabrera; Maram Alotaiby; Anne M Miermont; Anna T Riegel; Priscilla A Furth
Journal:  Mol Endocrinol       Date:  2011-02-03

2.  The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.

Authors:  Mark P Fereshteh; Maddalena T Tilli; Sung Eun Kim; Jianming Xu; Bert W O'Malley; Anton Wellstein; Priscilla A Furth; Anna T Riegel
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

3.  Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation.

Authors:  Larbi Amazit; Luigi Pasini; Adam T Szafran; Valeria Berno; Ray-Chang Wu; Marylin Mielke; Elizabeth D Jones; Maureen G Mancini; Cruz A Hinojos; Bert W O'Malley; Michael A Mancini
Journal:  Mol Cell Biol       Date:  2007-07-23       Impact factor: 4.272

Review 4.  The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer.

Authors:  Tyler Lahusen; Ralf T Henke; Benjamin L Kagan; Anton Wellstein; Anna T Riegel
Journal:  Breast Cancer Res Treat       Date:  2009-05-06       Impact factor: 4.872

5.  Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance?

Authors:  Petros D Grivas; Vassiliki Tzelepi; Georgia Sotiropoulou-Bonikou; Zinovia Kefalopoulou; Athanasios G Papavassiliou; Haralabos Kalofonos
Journal:  Int J Colorectal Dis       Date:  2009-02-06       Impact factor: 2.571

Review 6.  SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.

Authors:  Licen Li; Chu-Xia Deng; Qiang Chen
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

Review 7.  SRC-3 has a role in cancer other than as a nuclear receptor coactivator.

Authors:  Gang Ma; Yu Ren; Ke Wang; Jianjun He
Journal:  Int J Biol Sci       Date:  2011-05-24       Impact factor: 6.580

8.  Mouse models of estrogen receptor-positive breast cancer.

Authors:  Shakur Mohibi; Sameer Mirza; Hamid Band; Vimla Band
Journal:  J Carcinog       Date:  2011-12-22

9.  Phosphorylation of AIB1 at mitosis is regulated by CDK1/CYCLIN B.

Authors:  Macarena Ferrero; Juan Ferragud; Leonardo Orlando; Luz Valero; Manuel Sánchez del Pino; Rosa Farràs; Jaime Font de Mora
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

Review 10.  Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas.

Authors:  María José García-Barrado; Enrique J Blanco; María Carmen Iglesias-Osma; Marta Carretero-Hernández; Leonardo Catalano-Iniesta; Virginia Sanchez-Robledo; Manuel Carretero; Julio Joaquín Herrero; Sixto Carrero; José Carretero
Journal:  Int J Mol Sci       Date:  2017-11-01       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.